Physician
Integrated Regional Laboratories Pathology Services, LLC
Integrated Regional Laboratories Pathology Services, LLC was paid $200K by Medicaid between Mar 2022 and Dec 2024, across 63 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 16% of everything it billed.
33Billing provider infoINTEGRATED REGIONAL LABORATORIES PATHOLOGY SERVICES, LLC
DAVIE, FL 33328
DAVIE, FL 33328
33aNPI1417522863assigned 05/26/2021
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$200K
24GClaims140,107
24DCodes billed63
24AFirst – last monthMar 2022 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Florida
Rank by total paid#49 of 207
Median peer was paid$39K
This provider vs. median5.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RODKEY, JOHN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 28,215 | $47K | |
| 2023 | 64,865 | $98K | |
| 2024incomplete | 47,027 | $55K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 16% | 7,499 | 6,849 | $33K |
| 87276 | 9.1% | 9,664 | 8,894 | $18K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 8.8% | 78 | 69 | $18K |
| 80053 | Comprehensive metabolic panel | 6.0% | 9,286 | 7,532 | $12K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 4.2% | 1,177 | 1,000 | $8K |
| 85027 | 4.2% | 18,902 | 13,385 | $8K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.1% | 393 | 385 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.1% | 7,837 | 5,742 | $8K |
| 84703 | 4.0% | 5,045 | 4,383 | $8K | |
| 84702 | 3.9% | 2,454 | 1,943 | $8K | |
| 81025 | 3.8% | 6,109 | 5,431 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.6% | 1,267 | 1,167 | $7K |
51 more codes
| 87040 | 3.4% | 1,389 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.2% | 5,117 | $6K |
| 87275 | 3.2% | 2,481 | $6K | |
| 84484 | 1.8% | 4,260 | $4K | |
| 87487 | 1.5% | 375 | $3K | |
| 88307 | 1.5% | 52 | $3K | |
| 83880 | 1.1% | 1,092 | $2K | |
| 87070 | 1.1% | 4,830 | $2K | |
| 83690 | <1% | 5,025 | $2K | |
| 81001 | <1% | 7,928 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 585 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,106 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 164 | $1K |
| 87807 | <1% | 2,513 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 900 | $1K |
| 83605 | <1% | 1,115 | $1K | |
| 82803 | <1% | 197 | $1K | |
| 80076 | <1% | 2,547 | $996.65 | |
| 86850 | <1% | 1,922 | $904.63 | |
| 85730 | <1% | 2,451 | $862.73 | |
| 86900 | <1% | 4,302 | $826.56 | |
| 86880 | <1% | 791 | $806.15 | |
| 86901 | <1% | 3,958 | $722.57 | |
| 87496 | <1% | 139 | $576.40 | |
| 81003 | <1% | 3,471 | $559.68 | |
| 85610 | <1% | 2,604 | $511.58 | |
| 83735 | <1% | 893 | $486.56 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 180 | $476.11 |
| 87077 | <1% | 384 | $383.17 | |
| 85379 | <1% | 743 | $374.55 | |
| 85007 | <1% | 1,668 | $350.57 | |
| 82248 | <1% | 541 | $241.38 | |
| 86140 | <1% | 828 | $228.72 | |
| 82550 | <1% | 420 | $128.76 | |
| 85384 | <1% | 106 | $108.56 | |
| 85014 | <1% | 654 | $101.36 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 45 | $99.11 |
| 85018 | <1% | 660 | $65.39 | |
| 84100 | <1% | 220 | $58.57 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 57 | $50.54 |
| 84156 | <1% | 90 | $29.53 | |
| 87808 | <1% | 58 | $28.70 | |
| 82570 | <1% | 101 | $26.67 | |
| 87205 | <1% | 94 | $25.39 | |
| 85651 | <1% | 145 | $23.35 | |
| 84550 | <1% | 32 | $15.89 | |
| 86885 | <1% | 12 | $10.81 | |
| 84132 | <1% | 44 | $6.50 | |
| 84295 | <1% | 32 | $4.51 | |
| 86780 | 0% | 57 | $0.00 | |
| 82077 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRODKEY, JOHN (OWNER/VP OF OPERATIONS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.